by Team Attomarker | Jun 29, 2026 | Company News, Long Covid
A new article, co-published by members of the Attomarker team and published in Frontiers in Virology, presents the first body of work examining the effects of chronic SARS-CoV-2 exposure, tracking the quality of antibodies produced over time in a real-world,...
by Team Attomarker | Feb 26, 2026 | Company News
Why Attomarker chose a public funding route for work in Long Covid When someone tells you Long Covid is “too short term” to invest in, as was told to us by an institutional investor, they are not making a scientific claim. They are revealing a mindset. And that...
by admin | May 29, 2024 | Company News
Attomarker has been selected as one of the companies by Innovate UK for the following category: GBIP in Hyderabad and Bangalore, India – Antimicrobial Resistance, diagnostics and therapeutics Why India? India has recognised the importance of AMR, and the Indian...
